Pharmacoeconomic evaluation of influenza vaccination programs in elderly in Italy
Iannazzo S, Sacchi V. – Farmeconomia e percorsi terapeutici 2009; 10(2): 59-72
Solifenacin in the treatment of overactive bladder syndrome in italian patients: pharmacoeconomic evaluation
Pradelli L, Iannazzo S. – Journal of Medical Economics 2009; 12(1): 25-35
Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy
Bamfi F, Basso F, Aglietta M, Bengala C, Lorusso V, Pronzato P, Cavallo MC, Zaniolo O, Iannazzo S. – Farmeconomia e percorsi terapeutici 2009; 10(1): 33-46
Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy
Benucci M, Iannazzo S, Sabadini L. – Farmeconomia e percorsi terapeutici 2009; 10(1): 19-31
Budget impact analysis of use of aliskiren in hypertension on the italian health care system
Zaniolo O, Pradelli L. – Farmeconomia e percorsi terapeutici 2009; 10(1): 5-18
Maraviroc (celsentri) in HIV treatment
Sacchi V. – Farmeconomia e percorsi terapeutici 2008; 9(4): 219-222. Edited by AdRes Health Economics & Outcomes Research
Telbivudine (sebivo) in patients with hepatitis B virus (HBV) chronic infection
Sacchi V. – Farmeconomia e percorsi terapeutici 2008; 9(4): 215-218. Edited by AdRes Health Economics & Outcomes Research
Usefulness and limitation of ddd and pdd analyses. 12 months of solid oral antipsychotics prescribing data for the nhs-reimbursed treatment of schizophrenia in Italy
Pradelli L. – Farmeconomia e percorsi terapeutici 2008; 9(4): 191-196
Daptomycin (cubicin) in patients with complicated skin or soft-tissue infections
Sacchi V. – Farmeconomia e percorsi terapeutici 2008; 9(3): 163-166. Edited by AdRes Health Economics & Outcomes Research
Entecavir (baraclude) in patients with chronic hepatitis B virus (HPV) infection
Sacchi V. – Farmeconomia e percorsi terapeutici 2008; 9(3): 157-161. Edited by AdRes Health Economics & Outcomes Research
Cost-efficacy analysis of hormonal treatments for advanced prostate cancer
Iannazzo S, Pradelli L. – Farmeconomia e percorsi terapeutici 2008; 9(3): 147-156
Budget impact of vildagliptin
Zaniolo O, Sacchi V, Pradelli L. – Farmeconomia e percorsi terapeutici 2008; 9(3): 137-146
Pharmacoeconomic analysis of valsartan for the treatment of chronic congestive heart failure in Italy
Iannazzo S, Pradelli L, Zaniolo O. – Farmeconomia e percorsi terapeutici 2008; 9(3): 125-135
Rotigotine patches (neupro) in early parkinson’s disease
Sacchi V. – Farmeconomia e percorsi terapeutici 2008; 9(2): 115-119. Edited by AdRes Health Economics & Outcomes Research
Natalizumab (tysabri) in multiple sclerosis patients
Sacchi V. – Farmeconomia e percorsi terapeutici 2008; 9(2): 109-114. Edited by AdRes Health Economics & Outcomes Research
Sartans: differences, similitudes and costs
Zaniolo O, Iannazzo S. – Farmeconomia e percorsi terapeutici 2008; 9(2): 69-88
Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis
Iannazzo S, Pradelli L. – Farmeconomia e percorsi terapeutici 2008; 9(1): 5-14
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (cinv) in Italy: pharmacologic, clinical and economic aspects
Pradelli L, Eandi M. – Tumori 2008; 94: 26-32
Parnaparin: review of the literature
Pradelli L. – Farmeconomia e percorsi terapeutici 2008; 9(1): 27-40
La schizofrenia: percorsi diagnostico-terapeutici e costo di malattia
Zaniolo O, Pradelli L. – Profili in Farmacoeconomia 2008; 6
Economic evaluation of treatment with orlistat in italian obese patients
Iannazzo S, Zaniolo O, Pradelli L. – Curr Med Res Opin 2008; 24(1): 63-74
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects
Pradelli L, Eandi M. – Tumori 2008; 94: 26-32
Profilo farmacologico, clinico ed economico dell’associazione fissa di beclometasone dipropionato e formoterolo in formulazione extra-fine nella terapia di pazienti con asma bronchiale
Cremonesi G, Pradelli L. – Profili in Farmacoeconomia 2008; 7
Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe copd patients
Dal Negro RW, Eandi M, Pradelli L, Iannazzo S. – Int J Chron Obstruct Pulmon Dis 2007; 2(2): 169-176
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects
Pradelli L, Eandi M. – Farmeconomia e percorsi terapeutici 2007; 8(2): 71-80
Il disturbo bipolare: percorsi diagnostico-terapeutici e costo di malattia
Zaniolo O, Pradelli L. – Profili in Farmacoeconomia 2007; 4
Il costo dei disturbi ansiosi e depressivi e l’appropriatezza del percorso diagnostico-terapeutico nel paziente afferente al medico di medicina generale
Siracusano A, Niolu C, Pradelli L. – Profili in Farmacoeconomia 2007; 4
Profilo farmacologico clinico di paroxetina
Siracusano A, Niolu C, Pradelli L. – Profili in Farmacoeconomia 2007; 4
Bayesian statistic methods and theri application in probabilistic simulation models
Iannazzo S. – Farmeconomia e percorsi terapeutici 2007; 8(1): 5-13
Problematiche relative ai criteri auxologici nella diagnosi di bassa statura da deficit di GH e prescrizione dell’ormone della crescita ricombinante
Gilli G, Benso L, Pradelli L. -Clinical Management Issues 2007; 1: 165-170
Trattamento delle infezioni vaginali in gravidanza con metronidazolo e clotrimazolo topici
Pradelli L. – Clinical Management Issues 2007; 1(1): 21-29
Pay-back direct to regions: a new possibility for companies
Zaniolo O. – Farmeconomia e percorsi terapeutici 2007; 8(1): 47-48
Simvastatin: between clinics and health economics
Costa FV, Zaniolo O. – Farmeconomia e percorsi terapeutici 2007; 8(1): 27-45
Budget impact of rosiglitazone in type 2 diabetes
Zaniolo O, Bamfi F, Iannazzo S. – Farmeconomia e percorsi terapeutici 2007; 8(1): 15-26
Il ruolo terapeutico delle statine nella riduzione del rischio cardiovascolare
Pradelli L., Eandi M.. – Farmeconomia e percorsi terapeutici 2007; 8(2S): 8-12
Il progetto Sirio (Social Impact Of Respiratory Integrated Outcomes): un avanzamento nello studio delle patologie croniche respiratorie
Iannazzo S. – Multidisciplinary Respiratory Medicine 2006; 4: 5-6
Impatto clinico ed economico dell’ipertrofia prostatica benigna in Italia
Terrone C, Zaramella S, Zaniolo O. – Profili in Farmacoeconomia 2006; 3
Profilo clinico ed economico della tamsulosina
Zaniolo O, Pradelli L. – Profili in Farmacoeconomia 2006; 3
L’impatto clinico ed economico dell’infezione da HIV e delle sue terapie in Italia
Zaniolo O. – Profili in Farmacoeconomia 2006; 1
The health-economic models: practical aspects and management of uncertainty
Iannazzo S. – Farmeconomia e percorsi terapeutici 2006; 7(4): 239-245
Principi e scopi della farmacoeconomia
Eandi M, Pradelli L, Zaniolo O. – Profili in Farmacoeconomia 2006; 1
Economic and clinical value of levofloxacin
Eandi M, Zaniolo O. – Farmeconomia e percorsi terapeutici 2006; 7(4): 223-237
Clinical and pharmacoeconomic profile of esomeprazole in acid-related diseases
Zaniolo O. – Farmeconomia e percorsi terapeutici 2006; 7(3): 155-170
The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease
Pradelli L, Zaniolo O. – Farmeconomia e percorsi terapeutici 2006; 7(3): 141-154
Pharmacoeconomic profile of vitamin d3: in the prevention of osteoporosis
Zaniolo O. – Farmeconomia e percorsi terapeutici 2006; 7(1): 71-82
Bayesian statistic methods and their application in probabilistic simulation models
Zaniolo O. – Farmeconomia e percorsi terapeutici 2006; 7(1): 21-35
L’impatto clinico ed economico del sovrappeso e dell’obesità
Zaniolo O. – Profili in Farmacoeconomia 2005; 0
Impiego di tramadolo nelle diverse patologie dolorose
Zaniolo O. – Farmeconomia e percorsi terapeutici 2005; 6(4): 385-396
Valutazione farmacoeconomica della prevenzione con picotamide vs acido acetilsalicilico dei pazienti diabetici con vasculopatia periferica
Iannazzo S, Pradelli L, Eandi M. – Farmeconomia e percorsi terapeutici 2005; 6(4): 377-384
Le benzodiazepine nel trattamento dell’ansia: profilo clinico e farmacoeconomico
Cascio B, Zaniolo O. – Farmeconomia e percorsi terapeutici 2005; 6(4): 353-363
